ENTO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENTO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-31), Entero Therapeutics's share price is $0.4804. Entero Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $1.77. Hence, Entero Therapeutics's PB Ratio of today is 0.27.
The historical rank and industry rank for Entero Therapeutics's PB Ratio or its related term are showing as below:
During the past 10 years, Entero Therapeutics's highest PB Ratio was 0.27. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Entero Therapeutics's average Book Value Per Share Growth Rate was -63.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Entero Therapeutics was -77.20% per year. The lowest was -77.20% per year. And the median was -77.20% per year.
The historical data trend for Entero Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entero Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
9.46 | - | - | 2.24 | 1.82 |
Entero Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.19 | 1.82 | 0.55 | 0.40 | 0.20 |
For the Biotechnology subindustry, Entero Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Entero Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Entero Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Entero Therapeutics's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.4804 | / | 1.765 | |
= | 0.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Entero Therapeutics (NAS:ENTO) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Entero Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarah Romano | officer: Chief Financial Officer | 271 WAVERLY OAKS ROAD, WALTHAM MA 02452 |
James Sapirstein | director, officer: President and CEO | 1517 SAN JACINTO, HOUSTON TX 77002 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
David Andrew Hoffman | director | 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431 |
Edward Borkowski | director | 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317 |
Mary Theresa Coelho | director | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Alastair Riddell | director | C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226 |
Vern Lee Schramm | director | 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461 |
Gregory Oakes | director | 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226 |
James Pennington | officer: CHIEF MEDICAL OFFICER | 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545 |
Daniel H Schneiderman | officer: CHIEF FINANCIAL OFFICER | 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226 |
Ross Edmund Burke Jr. | 10 percent owner | C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196 |
Johan M. Spoor | director, officer: President and CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Maged Shenouda | director | 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
Pelican Partners Llc | 10 percent owner | PO BOX 2422, WESTPORT CT 06880 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By Marketwired • 02-07-2025
By Marketwired • 04-15-2024
By Marketwired • 05-16-2024
By Marketwired • 07-31-2024
By Business Wire • 11-15-2024
By Marketwired • 11-14-2024
By Marketwired • 02-14-2025
By GuruFocus Research • 02-07-2024
By Marketwired • 08-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.